Photo from wikipedia
The efficacy and safety of palbociclib, a cyclindependent kinase 4/6 inhibitor, used in combination with fulvestrant was assessed in women with advanced breast cancer (ABC) whose disease had progressed during… Click to show full abstract
The efficacy and safety of palbociclib, a cyclindependent kinase 4/6 inhibitor, used in combination with fulvestrant was assessed in women with advanced breast cancer (ABC) whose disease had progressed during previous endocrine therapy, with a significant improvement of progression-free survival and good health-related quality of life. Wereport a case of an 80-year-old patientwith ABCwho presented a cutaneous and gastrointestinal vasculitis during treatment with palbociclib and fulvestrant. The skin biopsy was consistent with a leukocytoclastic vasculitis with immunoglobulin A deposits in dermal blood vessels. The symptoms disappeared with the arrest of palbociclib and fulvestrant treatment and a high dose corticotherapy.
Journal Title: Clinical Breast Cancer
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!